Glenmark Pharmaceuticals Limited
GLENMARK.NS
Get informed when a big investor buys or sells
+ FollowMarket Cap$661.85B
Close$
Share Statistics
| Market cap | $661.85 Billion |
|---|---|
| Enterprise Value | $656.02 Billion |
| Dividend Yield | $5.00 (0.22%) |
| Earnings per Share | $48.26 |
| Beta | 0.26 |
| Outstanding Shares | 282,200,000 |
Return
| Return on Equity | 17.10% |
|---|---|
| Return on Assets | 9.03% |
| Return on Invested Capital | 20.23% |
Valuation & Multiples
| P/E Ratio | 35.99 |
|---|---|
| PEG | 3.87 |
| Price to Sales | 3.65 |
| Price to Book Ratio | 6.16 |
| Enterprise Value to Revenue | 3.7 |
| Enterprise Value to EBIT | 23.97 |
| Enterprise Value to Net Income | 36 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 31, 2026
EPS Estimate
$17.30
Average shareholder expectationRevenue Estimate
$39.16 B
Average shareholder expectationNext Earnings Call
Expected Date
November 6, 2026
EPS Estimate
$15.55
Average shareholder expectationRevenue Estimate
$40.76 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Glenmark Pharmaceuticals Limited
16,946 employees
CEO: Glenn Mario Saldanha Glenmark Pharmaceuticals Limited, along with its associated businesses, specializes in the development, manufacture, and global distribution of pharmaceutical products. The company's market presence spans India, North America, Latin Amer...